Bryce Kerlin to Present Cutting-Edge Plasminogen Research at 2026 GRC
Bryce Kerlin, Professor of Pediatrics – Hematology at The Ohio State University, shared a post on LinkedIn:
”I’m excited to present my lab’s work at the Plasminogen Activation and Extracellular Proteolysis GRC, organized by Ze Zheng and Paul Kim in February 2026.
Hope to see you there:
The upcoming 2026 Plasminogen Activation and Extracellular Proteolysis will be taking place February 8-13, 2026, at the Four Points Sheraton / Holiday Inn Express, Ventura, California, USA.
Registration is now open! The conference program highlights the cutting-edge work being conducted in the field. To review the program and apply, please click here.
The deadline to complete registration for this prestigious event will close on January 18, 2026; however, interested applicants should submit their application earlier for consideration.
The 2026 Plasminogen Activation and Extracellular Proteolysis (GRS) Seminar will take place the weekend prior to the GRC and is a wonderful opportunity for graduate students and postdocs to present their research among their peers.
Please share these links with your colleagues and help us spread the word to those who may be interested in attending.”
Keep up with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia